NSE: LAURUSLABS | BSE: 540222

Expensive Performer

Download real time

617.35 14.30 (2.37%)

60.16% Gain from 52W Low

1.1M NSE+BSE Volume

NSE 19 May, 2025 11:02 AM (IST)

33,290.8

Market Cap

High in industry

1.2

Beta 1Year

High Volatility

Laurus Labs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LAURUSLABS, BSE:540222 Laurus Labs Ltd.

Laurus Labs Ltd.

22 Dec 2020

617.35

2.37%

Further, the company's foray in the lucrative biologics/biotech space through the acquisition of a majority stake in Richcore Lifesciences would be a key positive as it would create a new revenue stream. We interacted with the management of Laurus Labs Limited (Laurus) and their commentary suggests a robust growth outlook. Laurus' formulations business is gaining traction with the tender business, which accounts for around three-fourth of total formulation sales, is witnessing sturdy growth. Moreover, Laurus is expanding capacities, primarily through brownfield expansions to cater to increasing demand. The first leg of de-bottlenecking is...

KRChoksey released a Accumulate report for Laurus Labs Ltd. with a price target of 687.0 on 30 Apr, 2025.

Laurus Labs Ltd.

26 Nov 2020

617.35

2.37%

Richcore acquisition - A step towards strategic diversification

Buy: Laurus Labs Ltd.

Motilal Oswal

Laurus Labs' (LAURUS) has acquired 73% stake in Richcore Lifesciences (RICH) for a cash consideration of INR2.5b. The acquisition is a step towards building a vertically integrated biotech segment and adds a new lever to growth. It particularly provides capabilities in high growth areas of Recombinant (Rh)...

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

01 Nov 2020

617.35

2.37%

Laurus Labs

Accumulate: Laurus Labs Ltd.

Dolat Capital

Laurus reported robust 2Q beating our estimates primarily driven by stellar growth in formulations. Though majority growth is led by ARV tender based opportunities, leveraging its backward integration, Laurus has demonstrated commendable execution capability as the growth is volume led without any one-offs. Management remained confident of growth sustenance in 2H as well. In order to supplement future growth, Laurus has undertaken a massive capex program (Rs12bn) of which Rs5bn is allocated...

Number of FII/FPI investors increased from 237 to 259 in Mar 2025 qtr.

Laurus Labs Ltd.

30 Oct 2020

617.35

2.37%

Laurus Labs

Buy: Laurus Labs Ltd.

Sharekhan

Synthesis and API segments are on track for a double digit growth. Operating leverage, favorable mix to support OPM expansion. Strong growth prospects, visibility on earnings, healthy balance sheet and return ratios are key positives We retain a Buy recommendation with a revised PT of Rs 385. Q2FY2021 was yet another stellar quarter for Laurus Labs Ltd (Laurus). Sales stood at Rs. 1138.8 crore, translating to a sturdy rise of 60% y-o-y on the back of robust growth in the lucrative formulations business and a double digit growth in the generic API's. Operating margins surprised positively, surging 1351 bps y-o-y to 32.8%, aided by an expansion...

KRChoksey released a Accumulate report for Laurus Labs Ltd. with a price target of 687.0 on 30 Apr, 2025.

Laurus Labs Ltd.

30 Oct 2020

617.35

2.37%

Laurus Labs (BUY): Beat continues; expect a better H2 TP raised to Rs 410

Buy: Laurus Labs Ltd.

BOB Capital Markets Ltd.

Laurus Labs reported yet another record beat in Q2FY21 with no major one-offs.

Laurus Labs Ltd. has gained 27.64% in the last 6 Months

Laurus Labs Ltd.

29 Sep 2020

617.35

2.37%

Laurus Labs

Hold: Laurus Labs Ltd.

ICICI Securities Limited

Laurus Labs Ltd.'s price crossed above 30Day SMA today

Laurus Labs Ltd.

15 Sep 2020

617.35

2.37%

Laurus Labs

Buy: Laurus Labs Ltd.

ICICI Securities Limited

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

19 Aug 2020, 12:00AM

617.35

2.37%

Pharmaceuticals: Expensive e-pharmacy deals; Neutral impact for pharma majors

Buy: Laurus Labs Ltd.

BOB Capital Markets Ltd.

Media articles suggest growing consolidation in the e-pharmacy chain, i.e. Reliance-Netmeds and PharmEasy-Medlife.

Laurus Labs Ltd. has an average target of 633.50 from 4 brokers.

Laurus Labs Ltd.

01 Aug 2020

617.35

2.37%

Metamorphosis underway

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

1 August 2020 Laurus Labs (LAURUS) delivered all-time high quarterly PAT at INR1.7b. It is more than average of annual PAT over FY17-20. The company expects this to be sustainable on the back of diversified portfolio, increased customer base, addition of capacity for API/formulation and supported with better operating leverage. After a long wait, the efforts towards product development/building manufacturing base are reflected in the phenomenal financial performance. In fact, 1QFY21 redefines the earnings assessment over near to medium term. Our target PE remains unchanged and target price of INR1,215 at 17x 12M forward earnings factors just the earnings upgrade. Sustainability of growth momentum in FY22 can drive further re-rating. Reiterate Buy. LAURUS 1QFY21 revenues grew at a robust rate of 77% YoY to INR9.7b INR3.5b v/s INR1.1b YoY, Other API (14% of sales) revenue of INR1.3b v/s INR440m YoY, 37% YoY growth in CDMO (10% of sales), and 19% YoY growth in Anti-Viral API (35% of sales).